![]() |
|
|
Vol. 63, Issue 2, 378-382, February 2003
Department of Pharmacology, Weill Medical College of Cornell
University, New York, New York (M.K, N.S, R.L.); and Johnson & Johnson
Pharmaceutical Research and Development, San Diego, California
(W.-P.F.-L, T.W.L.)
We previously reported that histamine H3 receptors
(H3Rs) are present in cardiac sympathetic nerve endings
(cSNE) of animals and humans, where they attenuate norepinephrine (NE)
release in normal and hyperadrenergic states, such as myocardial
ischemia. The recent creation of a transgenic line of mice lacking
H3R provided us with the opportunity to assess the
relevance of H3R in the ischemic heart. We isolated SNE
from hearts of wild-type (H3R+/+) and knockout
(H3R
/
) mice and found that basal NE release
from H3R
/
cSNE was ~60% greater than
that from H3R+/+ cSNE. NE exocytosis evoked by
K+-induced depolarization of cSNE from
H3R+/+ mice was attenuated by activation of
either H3R or adenosine A1 receptors
(A1R). In contrast, NE release from cSNE of
H3R
/
was unaffected by H3R
agonists, but it was still attenuated by A1R activation.
When isolated mouse hearts were subjected to ischemia for 20 min, NE
overflow into the coronaries was 2-fold greater in the
H3R
/
hearts than in those from
H3R+/+ mice. Furthermore, whereas stimulation
of H3R or A1R reduced ischemic NE overflow from
H3R+/+ hearts by 50%, only A1R,
but not H3R activation, reduced NE release in
H3R
/
. Our data demonstrate that NE
release from cSNE can be modulated by various heteroinhibitory
receptors (e.g., H3R and A1R) and that
H3Rs are particularly important in modulating NE release in
myocardial ischemia. Inasmuch as excessive NE release is clinically recognized as a major cause of arrhythmic cardiac dysfunction, our
findings reveal a significant cardioprotective role of H3R on cSNE.
This article has been cited by other articles:
![]() |
C. Morrey, R. Estephan, G. W. Abbott, and R. Levi Cardioprotective Effect of Histamine H3-Receptor Activation: Pivotal Role of G{beta}{gamma}-Dependent Inhibition of Voltage-Operated Ca2+ Channels J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 871 - 878. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Schaefer, T. Machida, M. J. Broekman, A. J. Marcus, and R. Levi Targeted Deletion of Ectonucleoside Triphosphate Diphosphohydrolase 1/CD39 Leads to Desensitization of Pre- and Postsynaptic Purinergic P2 Receptors J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1269 - 1277. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Schaefer, T. Machida, S. Vorlova, S. Strickland, and R. Levi The plasminogen activator system modulates sympathetic nerve function J. Exp. Med., September 4, 2006; 203(9): 2191 - 2200. [Abstract] [Full Text] [PDF] |
||||